checkAd

     108  0 Kommentare 4D pharma to Present at the Microbiome Movement Drug Development Summit - Seite 3

    All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in the timing of clinical trial commencement, risks relating to the Company’s manufacturing facilities, and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission ("SEC"), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

    Seite 3 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    4D pharma to Present at the Microbiome Movement Drug Development Summit - Seite 3 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces Christophe Carite, Development Director, will …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer